Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month.

Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks ...

Fintel reports that on June 17, 2025, Piper Sandler downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from ...

Psychedelics as an adjunctive therapy to psychiatric counseling may be feasible for anxiety and mood disorders, but proper ...

According to reporting from the BBJ, VC funding in June was lighter than usual; however, when it came to M&As, Boston biotechs were busy.